Type 2 Diabetes – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Type 2
Diabetes Market Outlook
Thelansis’s “Type 2 Diabetes
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2025 To 2035” covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Type 2
Diabetes treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Type 2
Diabetes Overview
Type 2 diabetes is a chronic metabolic
condition in which the body becomes progressively less able to use insulin
effectively and eventually produces less of it, leading to elevated blood
glucose that, left unmanaged, damages blood vessels, nerves, kidneys, and other
organs over time. Management has moved well beyond a narrow focus on blood
sugar control, with current practice treating the condition as a broader
cardiometabolic disease that also touches cardiovascular risk, kidney function,
fatty liver disease, and body weight. This shift is reflected in how therapy is
sequenced, with GLP-1 receptor agonists and related incretin-based medicines,
including dual-acting agents combining GLP-1 and GIP activity, increasingly
used earlier in the treatment course, given their combined effects on glucose,
weight, and organ protection. SGLT2 inhibitors play a similar role,
particularly for patients with heart or kidney involvement. Advances continue
in insulin delivery too, with longer-acting formulations reducing dosing
frequency, and glucose monitoring is increasingly standard for daily
management. Weight loss is now treated as a foundational goal rather than a
secondary benefit.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment